捐助
发表于 2025-3-23 09:57:32
http://reply.papertrans.cn/23/2281/228051/228051_11.png
填料
发表于 2025-3-23 17:46:31
Treatment of Ph-Like Acute Lymphoblastic Leukemia Ph-like ALL across the age spectrum has subsequently led to current precision medicine trials investigating the therapeutic potential of tyrosine kinase inhibitor-based therapies for children, adolescents, and adults with Ph-like ALL. These efforts have been somewhat challenging to translate given
Facet-Joints
发表于 2025-3-23 20:01:11
Prophylaxis and Treatment of Central Nervous System (CNS) Acute Lymphoblastic Leukemiaotherapy. Despite great advancements, the CNS remains the most common site of extramedullary relapse, and treatment of CNS relapse remains clinically challenging in patients with ALL. This chapter will review current methods of diagnosing and treating CNS leukemia and evaluating risk of CNS relapse,
Thyroid-Gland
发表于 2025-3-23 23:15:51
http://reply.papertrans.cn/23/2281/228051/228051_14.png
都相信我的话
发表于 2025-3-24 03:48:44
The Development and Management of Treatment with Chimeric Antigen Receptor T Cell (CAR T)icities, the role of consolidation therapy following CAR T cell therapy, and the development of new cellular products to overcome observed mechanisms of resistance. Here we will review the relevant progress to date with the use of CAR T cells against B-ALL and discuss the limitations and future dire
legitimate
发表于 2025-3-24 08:56:36
Clinical Management of Acute Lymphoblastic LeukemiaFrom Bench to Bedsid
genuine
发表于 2025-3-24 13:44:57
Clinical Management of Acute Lymphoblastic Leukemia978-3-030-85147-7
我说不重要
发表于 2025-3-24 17:05:49
http://reply.papertrans.cn/23/2281/228051/228051_18.png
剥削
发表于 2025-3-24 20:06:57
Pierre-André Cornillon,Eric Matzner-Løberted agents for R/R disease is already having a positive impact. These approaches are currently being investigated in the frontline setting, bringing promise for continued outcome improvements, ideally with fewer adverse short- and long-term treatment effects.
MERIT
发表于 2025-3-25 00:52:01
B. Bauer,A. Bouchard,P. Tripon,S. Rigalccess of highly effective therapies also to older and less fit patients. The possibility of devising largely chemotherapy-free regimens and avoiding allogeneic HSCT in an increasing proportion of patients is becoming a credible concept and marks a paradigm change for treatment of acute leukemias.